NCT02509923View on ClinicalTrials.gov

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
DRUG

Z-215 10mg

Z-215 10mg, capsules

DRUG

Z-215 20mg

Z-215 20mg, capsules

DRUG

Rabeprazole Sodium 10mg

Rabeprazole Sodium 10mg tablets

DRUG

Rabeprazole Sodium 20mg

Rabeprazole Sodium 20mg tablets

Trial Locations (1)

Unknown

Tokyo

Sponsors
All Listed Sponsors
lead

Zeria Pharmaceutical

INDUSTRY

NCT02509923 - To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter